

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333

E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

6 February 2017

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(2 pages by email)

Dear Madam

BIT225 ACCELERATES HIV-1 VIRUS REDUCTION

Sydney, Australia, 6 February 2017: The Directors of Biotron Limited (ASX: BIT) are pleased to announce that an HIV-1 animal trial, as presented to the Company's Annual General Meeting and announced on 22 November 2016, has been completed.

The headline results from this study show that the addition of BIT225 significantly reduces HIV-1 viral loads beyond the current best anti-retroviral treatments for HIV-1 and accelerates the reduction of HIV-1 levels, when compared to combinations without BIT225.

The study was performed in recently developed mice whose immune system was replaced with human cells. This makes them susceptible to infection with HIV-1 and they are thus an ideal model for investigating new drug treatments in a fast and cost-effective manner.

These results indicate an enhancement by BIT225 of currently approved anti-HIV-1 drug-treatment regimes (combined Anti-Retroviral Therapy or cART).

Further, the results of this trial demonstrate that the addition of BIT225 to anti-retroviral treatment results in a delayed and slower rate of viral rebound when anti-viral drugs are stopped.

Some questions which might be asked:

1. Why an animal study?

It is ethically challenging to undertake a study in humans that requires patients to suspend their anti-HIV-1 treatment.

2. What does this mean for the treatment of HIV-1?

In addition to a faster and greater reduction of the HIV-1 viral load, the results of this study strongly suggest that BIT225 treatment may lead to eradication of one the key underlying viral reservoirs.

3. What is next?

Firstly, detailed analysis of the extensive data package from this animal study will be completed.

Secondly, the BIT225-009 Phase 2 human clinical trial, also as presented to the Company's Annual General Meeting and announced on 22 November 2016 will be expedited. This study, designed to confirm a similar benefit in humans, is expected to commence shortly. The results of the present study confirm the relevance and design of this clinical trial.

Thirdly, the fully analysed results will be presented in detail as soon as possible to an appropriate scientific conference and shared in confidence with potential commercial partners.

Biotron's Managing Director, Dr Michelle Miller noted, "This important study demonstrates that BIT225 attacks a different source of virus than do the current anti-HIV-1 drugs. BIT225 has the potential to play a key role in the eradication of HIV-1 by targeting and clearing HIV-1 from certain reservoirs. Eradication of HIV-1 is a major focus of several multinational pharmaceutical companies, and Biotron's BIT225 represents a unique commercial opportunity."

Yours sincerely

Peter J. Nightingale Company Secretary

pin8773

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller Managing Director Biotron Limited +61-(0)412313329 Rudi Michelson Monsoon Communications +61-3 9620 3333